Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men

Pignone, Michael; Earnshaw, Stephanie; McDade, Cheryl; Pletcher, Mark
November 2013
JGIM: Journal of General Internal Medicine;Nov2013, Vol. 28 Issue 11, p1483
Academic Journal
BACKGROUND: Recent data suggest that aspirin may be effective for reducing cancer mortality. OBJECTIVE: To examine whether including a cancer mortality-reducing effect influences which men would benefit from aspirin for primary prevention. DESIGN: We modified our existing Markov model that examines the effects of aspirin among middle-aged men with no previous history of cardiovascular disease or diabetes. For our base case scenario of 45-year-old men, we examined costs and life-years for men taking aspirin for 10 years compared with men who were not taking aspirin over those 10 years; after 10 years, we equalized treatment and followed the cohort until death. We compared our results depending on whether or not we included a 22 % relative reduction in cancer mortality, based on a recent meta-analysis. We discounted costs and benefits at 3 % and employed a third party payer perspective. MAIN MEASURE: Cost per quality-adjusted life year (QALY) gained. KEY RESULTS: When no effect on cancer mortality was included, aspirin had a cost per QALY gained of $22,492 at 5 % 10-year coronary heart disease (CHD) risk; at 2.5 % risk or below, no treatment was favored. When we included a reduction in cancer mortality, aspirin became cost-effective for men at 2.5 % risk as well (cost per QALY, $43,342). Results were somewhat sensitive to utility of taking aspirin daily; risk of death after myocardial infarction; and effects of aspirin on stroke, myocardial infarction, and sudden death. However, aspirin remained cost-saving or cost-effective (< $50,000 per QALY) in probabilistic analyses (59 % with no cancer effect included; 96 % with cancer effect) for men at 5 % risk. CONCLUSIONS: Including an effect of aspirin on cancer mortality influences the threshold for prescribing aspirin for primary prevention in men. If such an effect is real, many middle-aged men at low cardiovascular risk would become candidates for regular aspirin use.


Related Articles

  • Low-dose aspirin cost saving in CVD.  // PharmacoEconomics & Outcomes News;7/11/2009, Issue 582, p4 

    The article focuses on a study presented at the 69th Annual Scientific Sessions of the American Diabetes Association which showed that low-dose aspirin in patients with or without diabetes mellitus is cost saving for patients at a 4% cardiovascular disease (CVD) risk or higher in the U.S. The...

  • Daily Aspirin Usage Associated with Lower Cancer Mortality.  // JNCI: Journal of the National Cancer Institute;Aug2012, Vol. 104 Issue 16, pNP 

    The article reports on a study on the association of daily aspirin usage with lower overall cancer mortality published within the issue. The researchers used data on 100,139 men and women from the Cancer Prevention Study II Nutrition Cohort who had no prior history of cancer and had been taking...

  • Does long term aspirin prevent cancer? Moayyedi, Paul; Jankowski, Janusz A. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/1/2011, Vol. 342 Issue 7787, p5 

    The authors discuss a meta-analysis of randomized controlled trials (RCTs) on the use of aspirin to reduce the risk of non-fatal myocardial infarction, by Rothwell and colleagues, published in the 2010 issue of "Lancet." The meta-analysis found that cancer patients who took aspirin for almost...

  • Dietary glycaemic index, glycaemic load and subsequent changes of weight and waist circumference in European men and women. Du, H.; van der A, D. L.; van Bakel, M. M. E.; Slimani, N.; Forouhi, N. G.; Wareham, N. J.; Halkjær, J.; Tjønneland, A.; Jakobsen, M. U.; Overvad, K.; Schulze, M. B.; Buijsse, B.; Boeing, H.; Palli, D.; Masala, G.; Sørensen, T. I. A.; Saris, W. H. M.; Feskens, E. J. M. // International Journal of Obesity;Nov2009, Vol. 33 Issue 11, p1280 

    Objectives:To investigate whether dietary glycaemic index (GI) and glycaemic load (GL) were associated with subsequent weight and waist circumference change.Design:Population-based prospective cohort study.Setting:Five European countries, which are Denmark, Germany, Italy, The Netherlands and...

  • Cost-effectiveness of family history-based colorectal cancer screening in Australia. Ouakrim, Driss A.; Boussioutas, Alex; Lockett, Trevor; Hopper, John L.; Jenkins, Mark A. // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background: With 14.234 diagnoses and over 4047 deaths reported in 2007, colorectal cancer (CRC) is the second most common cancer and second most common cause of cancer-related mortality in Australia. The direct treatment cost has recently been estimated to be around AU$1.2 billion for the year...

  • Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Fraser, D M; Sullivan, F M; Thompson, A M; McCowan, C // British Journal of Cancer;7/29/2014, Vol. 111 Issue 3, p623 

    Background:Aspirin use has been associated with a reduced cancer incidence and fewer deaths from cancer. This study examined whether women with breast cancer prescribed aspirin postdiagnosis had improved survival.Methods:An observational, population cohort study was undertaken using data linkage...

  • Daily, aspirin cuts cancer risk. Praities, Nigel // Pulse;3/28/2012, Vol. 72 Issue 11, p14 

    The article reports that the use of aspirin everyday can reduce the risk of deaths from cancer patients as compared with those who do not according to the study conducted by the researchers in Great Britain.

  • Daily low dose aspirin reduces risk of dying from some cancers. Kmietowicz, Zosia // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;12/11/2010, Vol. 341 Issue 7785, p1237 

    The article suggests that taking 75 milligrams of aspirin daily for more than five years reduces the risk of dying from a range of common cancers, according to the findings of a randomized controlled trial published in a 2010 issue of the journal "The Lancet."

  • Aspirin can cut cancer deaths.  // PRWeek (London);12/17/2010, p6 

    The article discusses a study conducted by a group of researchers, including Peter Rothwell of John Radcliffe Hospital and University of Oxford, that reveals that daily low dose of aspirin significantly decreases the risk of death from several types of cancer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics